JCO Precis Oncol August 2024 PMID 39178369

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.

Alberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, Ming Han, Zhihui Amy Liu, A Hal K Berman, Anna Spreafico, Albiruni Abdul Razak, Stephanie Lheureux, Aaron R Hansen, Deborah Lo Giacco, Farnoosh Abbas-Aghababazadeh, Judith Matito, Benjamin Haibe-Kains, Trevor J Pugh

Full text PDF Download social card

Mentions

Peak: 6 in Sep 2024

across 4 sources since Aug 2024

Extended reach

30,016

potential audience

Total likes

Video views

Mentions per month

Aug 2024 – Feb 2025

Where it's discussed

X / Twitter11 posts
News4 articles
Bluesky1 posts
YouTube1 videos

AI synopsis

What people are saying

Participants mainly express positive reception and recognition of the study's potential, calling it a 'significant' or 'innovative' approach, with phrases such as 'associates with clinical outcomes' and references to the article's relevance for personalized medicine. The tone is predominantly informative and hopeful, signaling a belief in the study's importance but with some engaged also discussing specific biomarkers like VIGex and ctDNA that hint at deeper interest and understanding.

AgreementModerate agreement

Most discussions acknowledge the importance of the study, highlighting its contribution to personalized cancer treatment and biomarker analysis, thus showing general agreement with its significance.

InterestHigh interest

The high interest score reflects curiosity about the novel combination of transcriptome and ctDNA analysis and its implications for treatment outcomes, as evident from enthusiastic language and calls to access full articles.

EngagementModerate engagement

Posts demonstrate moderate depth, with some discussing specific methods like the use of VIGex and circulating tumor DNA, while others merely share links or superficial summaries.

ImpactModerate impact

The discussions suggest the findings could influence future research and clinical practice, but emphasis remains on the potential rather than confirmed change, leading to a moderate impact score.

Abstract in brief

The study investigates the effectiveness of VIGex, a gene expression classifier, combined with circulating tumor DNA (ctDNA) measurements, in predicting clinical outcomes for patients with advanced solid tumors treated with pembrolizumab, an immunotherapy drug.
Results showed that patients classified as VIGexHot had better objective response rates, higher overall survival, and longer progression-free survival compared to other subgroups, especially when combined with changes in ctDNA levels.
Incorporating ctDNA data with VIGex classification enhances the ability to predict treatment success, suggesting that this combined biomarker approach could improve personalized treatment strategies for immunotherapy patients.]

Read the full abstract

All mentions

Biomarker Analysis Predicts Pembrolizumab Outcomes in Solid Tumors

This study investigates the effectiveness of VIGex, a gene expression classifier, combined with circulating tumor DNA measurements, in predicting clinical outcomes for patients with advanced solid tumors treated with…

ASCO Podcasts · Dec 18, 2024 45 views

bibliotecahuvh.bsky.social

@bibliotecahuvh.bsky.social · Bluesky

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab scientiasalut.gencat.cat/handle/11351... #ScientiaVH

Feb 14, 2025 View post →

BibliotecaHUVH

@BibliotecaHUVH · X

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab https://t.co/IWShawSIlJ #ScientiaVH

Feb 14, 2025 · 2,313 followers View post →

Arantxa Mena

@Arantxa1976 · X

RT @AhernandoCalvo:

Sep 5, 2024 · 3 shares · 245 followers View post →

Augusto_Valdivia

@Augusto_AVB · X

RT @AhernandoCalvo:

Sep 5, 2024 · 3 shares · 170 followers View post →

Vall d’Hebron Institute of Oncology (VHIO)

@VHIO · X

RT @AhernandoCalvo:

Sep 4, 2024 · 3 shares · 10,920 followers View post →

AHernando_Calvo

@AhernandoCalvo · X

Sep 4, 2024 · 17 likes · 3 shares · 326 followers View post →

Fundación ECO

@FundacionECO · X

Sep 3, 2024 · 1 like · 3,107 followers View post →

JCO Precision Oncology

@JCOPO_ASCO · X

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab: https://t.co/OY1pWxdnUb

Sep 3, 2024 · 5,307 followers View post →

FETTCC Fundación E. Tto. Tumores Cabeza y Cuello

@FundacionTTCC · X

RT @ttccgroup: Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanc…

Aug 30, 2024 · 2 shares · 255 followers View post →

SECOMCyC

@SECOMmxf · X

RT @ttccgroup: Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanc…

Aug 29, 2024 · 2 shares · 3,746 followers View post →

TTCC-GrupoTratamiento Tumores Cabeza y Cuello

@ttccgroup · X

Aug 29, 2024 · 2 likes · 2 shares · 1,233 followers View post →

BibliotecaHUVH

@BibliotecaHUVH · X

Aug 28, 2024 · 2,313 followers View post →

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Biomarker Analysis Predicts Pembrolizumab Outcomes in Solid Tumors